With the presence of new anticancer drugs increasing in the clinical field, the pharmaceutical industry has been demanding the authorities apply a new reimbursement model in Korea.

In addition to the existing immuno-oncology drugs, the emergence of antibody-drug conjugates (ADCs), which have proven effective in various cancers, has led to calls for different drug prices for each 'indication.’

# These calls have been mainly coming from multinational pharmaceutical companies that own new anticancer drugs, but they have been met with a lukewarm response in the field. The reason is that the system they requested considers the profitability of companies rather than the patients.